Categories
All-en HepC-en Journal

Hepatitis C Treatment in Indonesia

We will update these data from time to time. Please visit our social media and website regularly to get an update.

by Caroline Thomas

Since 2017, Indonesian government had committed to provide free treatment for patient with Hepatitis C,

Here is a list of free medication through Government programme:

  1. Sofosbuvir (must use in combination): provided for 4,000 patient per year.
  2. Daclatasvir (must use in combination): provided for 4,000 patient per year.

Besides Hepatitis-C treatment, Indonesian Government also provides 140.000 free rapid tests per year which can be accessed at selected Hospital references or State owned Medical Clinics through-out Indonesia regions.
For Reference Hospital list can be found at: http://pedulihatibangsa.id/service-directory/

Besides government support drugs we have collected infomation about drug that can be purchase individually from several pharmacist :

  1. Sofosbuvir (MyHep) + Daclatasvir (MyDekla) at Apotek Sehat Gemilang Jakarta
  2. Sofosbuvir (MyHep) + Daclatasvir (MyDekla) at Apotek Kimia Farma RSCM Jakarta.
  3. Sofosbuvir+Velpatasvir (Epclusa) at Apotek Crystal Farma Tangerang. 

For an unlisted place, please contact us and we will help you gather information.

Information about Sofosbuvir

Sofosbuvir is a medicine used to treat Hepatitis C. This medication had already been approved in Europe on January 2014 for adult treatment with all of chronic Hepatitis C genotypes.

For some cases, Sofosbuvir will be first interferon-free therapy choice of treatment. Treatment with Sofosbuvir showed a success number in reducing long-term risks of Hepatitis C with the likes of liver cancer or liver failure.

Sofosbuvir is one of the direct agent antivirus that disrupts life cycle of Hepatitis C virus (HCV). This drug works with inhibiting polymerase enzyme, an enzyme used by virus to replicate itself. Sofosbuvir must be used in conjunction with other drugs.

Sofosbuvir is used for adult patients with chronic Hepatitis C and all of HCV virus genotypes (1,2,3,4,5 and 6).

Sofosbuvir can be used for Hepatitis C first-time patient (treatment-naive) and recurrent treatment for patients with failed first-interferon therapy (treatment experience)

Sofosbuvir also had been tested for patient with HIV co-infection. Response rate and side effects of Sofosbuvir is similar to patient with HIV-negative, and sofosbuvir does not interacts with HIV medications. People with HIV and Hepatitis C (HCV) co-infection who wish to use Sofosbuvir, must be under doctor supervision who has experience in treating both disease.

Information about Daclatasvir

Dacltasavir is other drug used to treat Hepatitis C. This medication also had already been approved in Europe on August 2014. In the beginning, Daclatasvir can only be used to genotype 1-4 o HCV, but nowadays Daclatasvir can be used to treat all genotypes.

Treatment with Daclatasvir also showed a success number in reducing long-term risks of Hepatitis C with the likes of liver cancer or liver failure.

Daclastavir is also a direct agent antivirus that disrupts life cycle of Hepatitis C virus (HCV).

Daclatasvir is a first approved NS5A protein inhibitor, which can be used to by virus to reproduce itself.

Daclatasvir must be used in conjunction with other drugs.

Daclatasvir is used for adult patients with chronic Hepatitis C and all of HCV virus genotypes (1,2,3,4,5 and 6).

Daclastasvir can be used for Hepatitis C first-time patient (treatment-naive) and recurrent treatment for patients with failed first-interferon therapy (treatment experience)

HIV medicationDrug interactionDosage adjustment
Atazanavir/ritonavirDaclatasvir level increasingFrom 60mg to 30mg once daily.
IndinavirDaclatasvir level increasingFrom 60mg to 30mg once daily.
NelfinavirDaclatasvir level increasingFrom 60mg to 30mg once daily.
SaquinavirDaclatasvir level increasingFrom 60mg to 30mg once daily.
CobicistatDaclatasvir level increasingFrom 60mg to 30mg once daily except patient with combination drug use of Darunavir and cobicistat.
EfavirenzDaclatasvir level decreasingFrom 60mg to 90mg once daily.
EtravirineDaclatasvir level decreasingFrom 60mg to 90mg once daily.
NevirapineDaclatasvir level decreasingFrom 60mg to 90mg once daily.
Drug interactions table source: https://www.rxlist.com/daklinza-drug.htm#interactions

Information about Sofosbuvir/Velpatasvir (Epclusa)

Sofosbuvir + Velpatasvir combination (NS5A and NS5B inhibitors) is the first available combined single pil regiment and very effective for all HCV genotypes (1-6). This drug gave out therapy choice without interferon which needed to patients with:

  • Patient who has cirrhosis compensation with genotype 3.

For patient with HIV-HCV co-infection, please pay attention to drug interaction table:

  • Green: Safe to used in conjunction.
  • Yellow: Used with strict supervision.
  • Red: Contraindication

Feature image : Electron micrographs of hepatitis C virus purified from cell culture. Scale bar is 50 nanometers. Courtesy of the Center for the Study of Hepatitis C, The Rockefeller University.
HCV_pictures.png: Maria Teresa Catanese, Martina Kopp, Kunihiro Uryu , and Charles Rice derivative work: TimVickers (talk)

Leave a Reply

Your email address will not be published. Required fields are marked *